MedTrace Logo

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

NCT06415435 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-05-16

No results posted yet for this study

Summary

Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging.

The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.

Conditions

  • Melasma

Interventions

DEVICE

Radiofrequency Microneedling

Sylfirm X radiofrequency microneedling device

Sponsors & Collaborators

  • Benev Company, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-07-01
Completion
2024-10-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06415435 on ClinicalTrials.gov